Foundation Medicine launches genomic profiling test for solid tumors

Foundation Medicine (NSDQ:FMI) today launched the first FDA-approved comprehensive genomic profiling assay for all solid tumors in the U.S.

The test, FoundationOne CDx, is designed to detect specific genomic alterations and help doctors make personalized treatment decisions for their patients.

Get the full story at our sister site, Drug Delivery Business News.

The post Foundation Medicine launches genomic profiling test for solid tumors appeared first on MassDevice.

from MassDevice https://ift.tt/2E7fWIR